United States SGLT2 Inhibitor Market was valued at USD 1.8 Billion in 2022 and is projected to reach USD 3.8 Billion by 2030, growing at a CAGR of 9.6% from 2024 to 2030.
The Rise of SGLT2 Inhibitors in the US: A Deep Dive into Market Dynamics
The US Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors market has experienced significant growth in recent years, driven by the increasing prevalence of type 2 diabetes and the drugs' multifaceted benefits. SGLT2 inhibitors, such as canagliflozin, dapagliflozin, and empagliflozin, not only aid in glycemic control but also offer cardiovascular and renal advantages, making them a cornerstone in modern diabetes management.
Market Overview
Market Size and Growth: In 2022, the US SGLT2 inhibitor market was valued at approximately $4,146.3 million and is projected to reach $6,623.5 million by 2030, exhibiting a compound annual growth rate (CAGR) of 6.03% during the forecast period. citeturn0search0
Leading Products: Jardiance (empagliflozin) leads the market with a 40% share, followed by Farxiga/Forxiga (dapagliflozin) at 35%, and Invokana (canagliflozin) at 20%. citeturn0search2
Driving Factors
Rising Diabetes Prevalence: The increasing incidence of type 2 diabetes fuels the demand for effective treatments.
Expanded Therapeutic Benefits: Beyond glucose control, SGLT2 inhibitors have been approved for managing heart failure and chronic kidney disease, broadening their clinical applications.
Clinical Efficacy: Studies have demonstrated that SGLT2 inhibitors significantly reduce the risk of hospitalization for heart failure, providing substantial benefits to patients with both reduced and preserved ejection fraction. citeturn0search1
Challenges
Side Effects: Potential adverse effects, such as urinary tract infections and dehydration, may limit patient adherence.
Competition: The presence of alternative diabetes treatments, including metformin and GLP-1 receptor agonists, presents competitive challenges.
Cost Considerations: High medication costs can be a barrier for patients without adequate insurance coverage.
Distribution Channels
Hospital Pharmacies: In 2023, hospital pharmacies accounted for approximately 60% of the market share, reflecting their role in acute care settings. citeturn0search2
Online Pharmacies: This segment is experiencing rapid growth due to the convenience of home delivery and increased patient confidentiality.
Future Outlook
The US SGLT2 inhibitor market is poised for continued growth, driven by ongoing research into additional therapeutic applications and a focus on combination therapies. As the understanding of these drugs' benefits expands, their role in managing conditions beyond diabetes, such as heart failure and chronic kidney disease, is expected to solidify, ensuring their prominence in the pharmaceutical landscape.
Get an In-Depth Research Analysis of the US SGLT2 Inhibitor Market Size And Forecast [2025-2032]
Eli Lilly
Boehringer Ingelheim
Johnson & Johnson
AstraZeneca
Merck
Pfizer
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the US SGLT2 Inhibitor Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the US SGLT2 Inhibitor Market
Dapagliflozin
Canagliflozin
Empagliflozin
Ertofazol
Remogliflozin
Oral
Injectable
Adults (18-65 Years)
Elderly (65 Years and Older)
With Metformin
With Insulin
With DPP-4 Inhibitors
Type 2 Diabetes Mellitus
Heart Failure
Chronic Kidney Disease
Weight Management
US (United States, US and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ SGLT2 Inhibitor Market Research Analysis
1. Introduction of the US SGLT2 Inhibitor Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. US SGLT2 Inhibitor Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. US SGLT2 Inhibitor Market, By Type
6. US SGLT2 Inhibitor Market, By Application
7. US SGLT2 Inhibitor Market, By Geography
US
Europe
Asia Pacific
Rest of the World
8. US SGLT2 Inhibitor Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading US Research and Consulting firm servicing over 5000+ US clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/